|
KMID : 0941820180280040320
|
|
Korean Journal of Clinical Pharmacy
2018 Volume.28 No. 4 p.320 ~ p.332
|
|
|
Effect of SLCO1B1 T521C on Statin-induced Myotoxicity: A Systematic Review and Meta-analysis
|
|
Lee Young-Sook
Chun Pu-Soon
|
|
|
Abstract
|
|
|
Background: This study was performed to clarify the effect of SLCO1B1 T521C on statin-induced myotoxicity.
Methods: ThePubMed, Embase, Ovid, and Cochrane Library databases were searched for all published studies between database inception andApril 2018. Using Review Manager 5, the pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were determinedto assess the effect of SLCO1B1 T521C on statin-induced myotoxicity by using different genetic models.
Results: Elevenobservational studies and one randomized controlled trial were included in the meta-analysis. The pooled analysis showed that theincidence of statin-induced myotoxicity was significantly associated with the SLCO1B1 521C variant allele. Among patients usingstatins, the incidence of myotoxicity was higher in those carrying the 521TC or 521CC variant than in those carrying the 521TTvariant in the dominant model (TC + CC vs TT, OR: 1.57; 95% CI: 1.20, 2.05; p = 0.001). The 521TC genotype was associated witha higher risk of myotoxicity than the 521TT genotype (OR: 1.42; 95% CI: 1.09, 1.86; p = 0.009). Furthermore, the incidence ofmyotoxicity was higher in 521CC carriers than in 521TC carriers (OR: 1.40; 95% CI: 1.06, 1.83; p = 0.02) and noticeably higher in521CC carriers than in 521TT carriers (OR: 2.26; 95% CI: 1.23, 4.17; p = 0.009).
Conclusion: The identification of individuals with theSLCO1B1 521C variant allele prior to the initiation of statin therapy might be useful to predict the risk of toxicity development,determine the individual dose, and prevent myotoxicity.
|
|
|
KEYWORD
|
|
|
SLCO1B1 T521C polymorphism, statin, myotoxicity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|